Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1997-08-21
1999-03-30
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514573, A61K 31557
Patent
active
058890521
ABSTRACT:
Disclosed is the use of cloprostenol and fluprostenol analogues for the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic compositions comprising said compounds.
REFERENCES:
patent: 3954881 (1976-05-01), Bowler
patent: 4159343 (1979-06-01), Skuballa et al.
patent: 4256745 (1981-03-01), Skuballa et al.
patent: 4321275 (1982-03-01), Bowler et al.
patent: 4599353 (1986-07-01), Bito et al.
patent: 5173507 (1992-12-01), DeSantis et al.
patent: 5288754 (1994-02-01), Woodward et al.
patent: 5352708 (1994-10-01), Woodward et al.
patent: 5480900 (1996-01-01), DeSantis et al.
patent: 5510383 (1996-04-01), Bishop et al.
patent: 5565492 (1996-10-01), DeSantis et al.
patent: 5605922 (1997-02-01), DeSantis et al.
patent: 5665773 (1997-09-01), Klimko et al.
Bito et al., "The Ocular Effects of Prostaglandins and the Therapeutic Potential of New PGF.sub.2 .alpha. Analog, PhXA41 (latanoprost), for Glaucoma Management," J. of Lipid Mediators, 6:535-543 (1993).
Burke et al., "Prostaglandin F .sub.2 .alpha. Effects on Rabbit IOP Negatively Correlate With Classical PGF .sub.2 .alpha. Receptor Stimulation" ARVO, Sarasota, Florida, vol. 29, p. 325, May 1-6, 1988.
Coleman et al., "Prostanoids and their Receptors," Comprehensive Medicinal Chemistry, vol. 3, 12.11:643-714.
Narumiya et al., "Structure and Function of Prostanoid Receptors," J. of Lipid Mediators, 6:155-161 (1993).
Resul et al., "Phenyl-Substituted Prostaglandins: Potent and Selective Antiglaucoma Agents," J. Med. Chem., 36:243-248 (1993).
Stjernschantz et al., "Phenyl Substituted Prostaglandin Analogs for Glaucoma Treatment," Drugs of the Future, 17(8):691-704 (1992).
The Merck Index, 11th Ed., p. 375 (1989).
The Merck Index, 11th Ed., pp. 656-657 (1989).
Woodward et al., "Definition of Prostanoid Receptor Subtypes by Radioligand Binding and the Effects of Selective Agonists on Intraocular Pressure" Ex. Eye Res. 55(1):s91 (1992).
Woodward et al., "Intraocular Pressure Effects of Selective Prostanoid Receptor Agonists Involve Different Receptor Subtypes According to Radioligand Binding Studies," J. of Lipid Mediators, 6:545-553 (1993).
Zajacz et al., "Effect on Human Eye of Prostaglandin and a Prostaglandin Analogue Used to Induce Abortion,"IRCS Medical Science: Clinical Medicine: Clinical Pharmacology & Therapeutics: Drug Metabolism & Toxicology: The Eye: Reproduction, Obstetrics & Gynecology, 4:316 (1976).
Bishop John E.
Klimko Peter G.
Sallee Verney L.
Zinke Paul W.
Alcon Laboraties, Inc.
Copeland Barry L.
Raymond Richard L.
LandOfFree
Use of cloprostenol and fluprostenol analogues to treat glaucoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of cloprostenol and fluprostenol analogues to treat glaucoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cloprostenol and fluprostenol analogues to treat glaucoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1215595